✦ LIBER ✦

A prospective clinical trial of lenalidomide with topotecan in women with advanced epithelial ovarian carcinoma

✍ Scribed by Jori S. Carter; Levi S. Downs

Book ID: 106285426
Publisher: Springer
Year: 2011
Tongue: English
Weight: 163 KB
Volume: 16
Category: Article
ISSN: 1341-9625
DOI: 10.1007/s10147-011-0243-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A prospective randomized trial of thalid

A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma

✍ Levi S. Downs Jr.; Patricia L. Judson; Peter A. Argenta; Rahel Ghebre; Melissa A 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

## Abstract ## BACKGROUND. Thalidomide is an antiangiogenic agent with immune modulating potential. The objective of this study was to determine response rates among women who were treated for recurrent ovarian cancer using topotecan with or without thalidomide. ## METHODS. Women were enrolled i

A phase II clinical trial of topotecan a

A phase II clinical trial of topotecan and carboplatin in patients with newly diagnosed advanced epithelial ovarian cancer

✍ F. VECCHIONE; R. FRUSCIO; T. DELL’ANNA; A. GARBI; R. GARCIA PARRA; S. CORSO; A.A 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

Tamoxifen in combination with cytotoxic

Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial

✍ Peter E. Schwartz; Joseph T. Chambers; Ernest I. Kohorn; Setsuko K. Chambers; He 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 536 KB

Efficacy of low-dose topotecan in second

Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma

✍ Bo Gronlund; Heine H. Hansen; Claus Høgdall; Svend A. Engelholm 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB

## Abstract ## BACKGROUND The high incidence of dose‐limiting myelosuppresion using the U.S. Food and Drug Administration‐approved topotecan dose of 1.5 mg/m^2^ for 5 days every 3 weeks may have limited its utility in the treatment of patients with epithelial ovarian carcinoma. The objective of th

Luteinizing hormone-releasing hormone ag

Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in patients with advanced ovarian carcinoma: A prospective double blind randomized trial

✍ Günter Emons; Olaf Ortmann; Hanns-Martin Teichert; Horst Fassl; Udo Löhrs; Stig 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 908 KB

## Background: Several lines of evidence suggest that the proliferation of ovarian carcinoma might be stimulated by gonadotrophins. a number of phase i/phase ii clinical trials have reported that the suppression of endogenous luteinizing hormone and follicle-stimulating hormone secretion by luteini

A Phase II trial of topotecan and gemcit

A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma

✍ David A. Rinaldi; Nancy A. Lormand; Joseph E. Brierre; James L. Cole; Brian C. B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB 👁 2 views

## Abstract ## BACKGROUND Multiple trials have been performed to evaluate second‐line clinical chemotherapy in patients with advanced nonsmall cell lung carcinoma (NSCLC). However, no single agent or combination has demonstrated superior activity. ## METHODS Patients with advanced NSCLC who had